We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bacterium Evaluated as Potential Multiple Sclerosis Trigger

By LabMedica International staff writers
Posted on 06 Nov 2013
A bacterium has been identified that may trigger multiple sclerosis (MS), a chronic, debilitating disorder that damages myelin forming cells in the brain and spinal cord.

Clostridium perfringens type B, an epsilon toxin-secreting bacillus, has been isolated for the first time from a young woman at clinical presentation of MS with actively enhancing lesions on brain seen by magnetic resonance imaging (MRI).

A scientific team from Weill Cornell Medical College (New York, NY, USA) tested banked blood and spinal fluid (CSF) from both MS patients and healthy controls for antibody reactivity to the epsilon toxin (ETX). More...
Western blots were performed using human sera or CSF as the primary antibody. They found that levels of epsilon toxin antibodies in MS patients were 10 times higher than in the healthy controls, as the blood of only one out of 100 control participants showed an immune reaction to the toxin.

The team also examined stool samples from both 30 MS patients and 31 healthy controls enrolled in a clinical study. The mean age of healthy controls was 46.7 years and the mean age of MS subjects was 42.0 years. Of the healthy controls, 14 of 31 were female, and of the MS subjects, 22 of 30 were female. The investigators found that 52% of healthy controls carried the C. perfringens A subtype compared to 23% of MS patients. For CSF, 6 of 62 MS patients, and 1 of 40 controls, were positive for ETX immunoreactivity. For the analysis of sera, 6 of 56 MS patients, and none of the 60 controls were seroreactive to ETX.

Timothy Vartanian, MD, PhD, a professor of neurology and neuroscience, said, “While it is clear that new MS disease activity requires an environmental trigger, the identity of this trigger has eluded the MS scientific community for decades. Work is underway to test our hypothesis that the environmental trigger for MS lays within the microbiome, the ecosystem of bacteria that populates the gastrointestinal tract and other body habitats of MS patients.” 

Professor Vartanian added, “We are also investigating the possibility of developing small-molecule drugs that prevent the toxin from binding to its receptor. But one of my favorite approaches is development of a probiotic cocktail that delivers bacteria that compete with, and destroy, C. perfringens types B and D. It would be such a beautiful and natural way to treat the gastrointestinal system and solve the problem. We are also starting to work on this approach.” The study was published on October 16, 2013, in the journal Public Library of Science ONE.

Related Links:

Weill Cornell Medical College 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.